106 related articles for article (PubMed ID: 8824560)
1. Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma.
Teicher BA; Chen YN; Ara G; Emi Y; Kakeji Y; Maehara Y; Keyes S; Northey D
Int J Cancer; 1996 Sep; 67(6):864-70. PubMed ID: 8824560
[TBL] [Abstract][Full Text] [Related]
2. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
4. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
5. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy/stem cell support: comparison of mice and humans.
Teicher BA; Northey D; Yuan J; Frei E
Int J Cancer; 1996 Mar; 65(5):695-9. PubMed ID: 8598324
[TBL] [Abstract][Full Text] [Related]
7. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
9. Interaction of interleukin-11 (rhIL-11) with cytotoxic therapies in the human HT-29 colon carcinoma.
Teicher B; Ara G; Northey D
Int J Oncol; 1997 Jun; 10(6):1081-5. PubMed ID: 21533487
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
11. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
12. CAI: effects on cytotoxic therapies in vitro and in vivo.
Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
[TBL] [Abstract][Full Text] [Related]
13. Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo.
Teicher BA; Wong JS; Takeuchi H; Gravelin LM; Ara G; Buxton D
Cancer Chemother Pharmacol; 1998; 42(1):24-30. PubMed ID: 9619754
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Teicher BA; Holden SA; Goff DA; Wright JE; Tretyakov O; Ayash LJ
Cancer Chemother Pharmacol; 1996; 38(6):553-60. PubMed ID: 8823498
[TBL] [Abstract][Full Text] [Related]
16. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor PS-341 in cancer therapy.
Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
20. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
